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CO-OPERATIVE SCOPE FOR BIOTECHNOLOGY 
0 
Biotechnology - sometimes known as the 'life sciences' - has developed 
dr.a~tically in the las.t few years but, as in other fields of high technology, 
the European Community is failing to compete with rivals, the United States 
and Japan. Indeed, a US report prepared for the White House in May 1983 
practically dismisses the European effort, pointing out the Co1D11Unity's lack 
of qualified scientists and engineers (many of whom migrate to America), 
inadequate industry/university co-operation, and belated and insufficient R&D 
funding .. 
In addition to its efforts to stimulate devel9pment in informat~cs and. industrial 
R&D (1), .the European Commission has now submitted a framework plan (2) io the 
Council of Ministers designed to do the same for the new life sciences. ·· The 
scope in agriculture, health care and the envirotµnent is immense - som~ m~y 
think alarming - but though most of the Comunity countries have, in the. 1980s, 
launched their own progranmes, they are hampered as usual by fragmentation, 
lack of resources, and failure to take advantage of the common market. 
The Commission would like to see greater co111Don concentrat-ion on a number of 
specific areas of development as part of a coherent strategy which could stand 
up to American and Japanese competition. 
The life sciences 
The biological sciences cover a wide range of disciplines including biochemistry, 
genetics, microbiology, physiology, plant and animal anatomy, bio-pbysics, and 
so on. They have .all contributed to modern standards of food supply, health 
care, and control of the environment but today, according to the Commission, 
their potential for human welfare is even greater. This potential it de
1
fines 
as the 'new biotechnology' - a multi-disciplinary system which, pr9perly handled, 
should contribute significantly to the solution of many contemporary problems. 
Yet in this vital field the Co111Dunity is being outspent by the United States by 
a factor of 2:1 in public sector research and more in industry, and 'out-planned' 
by the Japanese with their. ten years of coherently planned approach.. Whil.e 
admitting that figures can only be tentative the Commission estimates (3) that 
public sector R&D expenditure stretching from the very narrow to overlapping 
agricultural and medical research ranges in the USA per annum from $200m - $550m 
compared with $156m to $380m in the European Conmunity. Japan, with a public 
expenditure of at least $50m p.a. utilises its resources in a particularly 
effective and coherent way, compared with the situation to date in most individual 
Community countries. 
(1) See BR ISEC/Bl/1983 
(2) COM(83) 672 and Annex, 4.10.1983 
(3) COM(83) 328 of 8 June 1983 . / .. 
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Conanunity weaknesses 
Although the Federal Republic of Germany has had outstanding industrial 
strength in all major areas of biotechnology, this is not reflected in the 
Co111Dunity as a whole. The Conanission points to fragmentation of research, 
shortages of technicians and scientists and, in particular to the absence 
of appropriate logistic support for laboratories in the shape of data ban!ks, 
patent counselling, and multi-disciplinary training. The situation is 
aggravated by the decision of many biotechnological experts to work in Anlerica, 
where scope and conditions are better. 
As in other technological fields the Community is not short of invention; its 
main weakness lies in general failure to exploit such inventions for practical 
and industrial purposes. The Commission's strategy seeks to change this state 
of affairs. 
Biotechnological potential 
In the Annex to its latest Communication the Cormnission recapitulates the 
potential of the new biotechnology for the future. These include: 
further industrial applications in such areas as monoclonal antibodies, 
preparation of new vaccines and so on leading to the creation of cell 
lines and strains of organisms displaying new properties; the construction 
of new types of reactors for bio-mass processing and the recycling of useful 
materials; and development of more reliable and less expensive methods of 
introducing, testing, and evaluating new products. 
wide opportunities in a developing market, where over 40 per cent of 
manufacturing output in a developed industrial country is biological in 
nature or origin, and therefore likely to be influenced or transformed 
by developments in biotechnology. 
strategic significance as a powerful tool for renewal and innovation of the 
economic base of contemporary society, particularly.in the chemical industries 
and in industries such as agro-feed, environment, and water treatment and 
distribution. 
A Community plan 
At the June 1983 European Council meeting in Stuttgart heads of government 
recognised the importance of a Community dimension for the new biotechnologies, 
and the Conmission's proposals are an extension of this recognition in the 
practical field. It recommends action in four major areas:-
a strong research base or critical mass based on a pooling of skills and 
an alliance of disciplines; 
support for research through 1111lti"!'-Oisciplinary training and suitable logistic 
backing; 
clearly defined regimes covering all stages from laboratory development and 
testing through marketing to post-marketing monitoring; 
economic and social impacts of biotechnology on health, agriculture and 
industry. Such impacts are particularly relevant to the Community's 
agricultural policy, and in the public health sector which has witnessed 
a rapid expansion of medical costs and the substantial replacement of the 
private customer by the state customer. 
In order to accomplish these ends the Cormnission recommends a five year programme 
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(1984-89) at an estimated cost of 200m ECU (£114m) (1) over the period which 
would concentrate on co-operation in multidisciplinary training and research 
both in the general 'horizontal' sector of information dissemination and 
logistic support, and in specific sectors related to agriculture and health 
care where industry finds few inducements because of commercial restraints or 
fragmentation of the coDDon market. Research activities would be complementedf 
by a training_progranane specifically designed to increase the numbers of trained 
technicians and scientists qualified in basic biotechnology - a multidisciplinary 
activity not now usually taught in universities. 
In addition the Commission proposes the establishment of an expanded series of 
networks to provide an ad hoe system of collaboration betwe·en individuals, 
specialised groups and institutions, coupled with an information base regularly 
updated to handle and disseminate material. The Connnission continually stresses 
the importance of seeing biotechnology disciplines and their effects as inter-
related, particularly where agri-industry, such as food processing and health 
are concerned, with their impacts not only at home but on the developing world. 
Biotechnological discoveries can, however, be harmful as well as beneficial. 
The plan, therefore, calls for increased collaboration with the Commission in 
devising safety regulations and in monitoring, taking account of the work of 
other interested organizations such as OECD, WHO and the Council of Europe. 
There is also need to give more consideration to the question of patents, and 
the Commission urges all Community countries to ratify both the European and 
the Community Patent Conventions, as a first but necessary step towards connnonly 
accepted regulations on this issue. 
(1) 1 ECU = 57p 
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ANNEX 
SUMMARY ESTIMATES BY COUNTRY OF PUBLIC EXPENDITURE ON BIOTECHNOLOGY R&D .I 
(M. ECUS - 1982/1983) 
Biotechnology "Biotechnology- (1) 
relevant" 
F .R .. Germany 36 
France 31 
United Kingdom 46 
Italy 13 
Netherlands 10 
Belgium 7 
Denmark, Greece, Ireland, Luxembourg: say 3 
146 
(U.S. $m 156 
132 
84 
59 
34 
26 
14 
6 
355 
378) 
(1) The biotechnology-relevant figure is on a broader basis, reflecting 
R&D expenditure in relevant medical, agro-food and life-sciences research. 
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